Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of ketamine in normal and schizophrenic volunteers
Autore:
Lahti, AC; Weiler, MA; Michaelidis, T; Parwani, A; Tamminga, CA;
Indirizzi:
Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Baltimore, MD 21228 USAUniv Maryland Baltimore MD USA 21228 iat Res Ctr, Baltimore, MD 21228 USA
Titolo Testata:
NEUROPSYCHOPHARMACOLOGY
fascicolo: 4, volume: 25, anno: 2001,
pagine: 455 - 467
SICI:
0893-133X(200110)25:4<455:EOKINA>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
HEALTHY-VOLUNTEERS; PHENCYCLIDINE; PSYCHOSIS; ASPARTATE; GLUTAMATE; BEHAVIOR; DRUGS; ANTAGONIST; DIAGNOSIS; MOVEMENTS;
Keywords:
schizophrenia; ketamine; psychosis; N-methyl-D-aspartate; glutamate; drug model;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
57
Recensione:
Indirizzi per estratti:
Indirizzo: Lahti, AC Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, POB 21247, Baltimore, MD 21228 USA Univ Maryland POB 21247 Baltimore MD USA 21228 ore, MD 21228 USA
Citazione:
A.C. Lahti et al., "Effects of ketamine in normal and schizophrenic volunteers", NEUROPSYCH, 25(4), 2001, pp. 455-467

Abstract

This study evaluates the effects of ketamine on healthy and schizophrenic volunteers (SVs) in an effort to define the detailed behavioral effects of the drug in a psychosis model. We compared the effects of ketamine on normal and SVs to establish the comparability of their responses and the extent to which normal subjects might be used experimentally as a model. Eighteen normal volunteers (NVs) and 17 SVs participated in ketamine interviews. Some (n = 7 NVs; n = 9 SVs) had four sessions with a 0.1-0.5 mg/kg of ketamineand a placebo; others (n = 11 NVs; n = 8 SVs) had two sessions with one dose of ketamine (0.3 mg/kg) and a placebo. Experienced research clinicians used the BPRS to assess any change in mental status over time and documentedthe specifics in a timely way. In both volunteer groups, ketamine induced a dose-related, short (< 30 min) increase in psychotic symptoms. The scoresof NVs increased on both the Brief Psychiatric Rating Scale (BPRS) psychosis subscale (p = .0001) and the BPRS withdrawal subscale (p = .0001), whereas SVs experienced an increase only in positive symptoms (p = .0001). Seventy percent of the patients reported an increase (i.e., exacerbation) of previously experienced positive symptoms. Normal and schizophrenic groups differed only on the BPRS withdrawal score. The magnitude of ketamine-induced changes in positive symptoms was similar, although the psychosis baseline differed, and the dose-response profiles over time were superimposable acrossthe two populations. The similarity between ketamine-induced symptoms in SVs and their own positive symptoms suggests that ketamine provides a uniquemodel of psychosis in human volunteers. The data suggest that the phencyclidine (PCP) model of schizophrenia maybe a more valid human psychosis/schizophrenia drug model than the amphetamine model, with a broader range of psychotic symptoms. This study indicates that NVs could be used for many informative experimental psychosis studies involving ketamine interviews.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 17:00:41